At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
STAR-TOR- REGISTRY FOR THE EVALUATION OF THE SAFETY, TOLERABILITY AND EFFICACY OF TEMSIROLIMUS (TORISEL), SUNITINIB (SUTENT) AND AXITINIB (INLYTA) FOR THE TREATMENT OF SUBJECTS WITH ADVANCED RENAL CELL CARCINOMA (MRCC), MANTLE CELL LYMPHOMA (MCL) AND GASTRO-INTESTINAL STROMA TUMOR (GIST).
In Brief
An observational study evaluating Temsirolimus, Sunitinib, and 1 other intervention for Carcinoma, Renal Cell, Advanced and 2 related conditions. Completed, enrolled 1,520 participants across 77 sites.
Detailed Summary
The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use
Study Details
Timeline
Interventions
Non-interventional study. Treatment decision already made before inclusion into the registry.
Non-interventional study. Treatment decision already made before inclusion into the registry.
Non-interventional study. Treatment decision already made before inclusion into the registry.
Non-interventional study. Treatment decision already made before inclusion into the registry.
Non-interventional study. Treatment decision already made before inclusion into the registry.